DE69936195D1 - Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus) - Google Patents

Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus)

Info

Publication number
DE69936195D1
DE69936195D1 DE69936195T DE69936195T DE69936195D1 DE 69936195 D1 DE69936195 D1 DE 69936195D1 DE 69936195 T DE69936195 T DE 69936195T DE 69936195 T DE69936195 T DE 69936195T DE 69936195 D1 DE69936195 D1 DE 69936195D1
Authority
DE
Germany
Prior art keywords
tacrolimus
formulation containing
gel formulation
pharmaceutical gel
tricyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69936195T
Other languages
English (en)
Other versions
DE69936195T2 (de
Inventor
Rinta Ibuki
Fumio Shimojo
Satoshi Ueda
Toshihiko Toyoda
Masayuki Yamanaka
Erika Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of DE69936195D1 publication Critical patent/DE69936195D1/de
Application granted granted Critical
Publication of DE69936195T2 publication Critical patent/DE69936195T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69936195T 1998-04-27 1999-04-26 Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus) Expired - Lifetime DE69936195T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP11727198 1998-04-27
JP11727198 1998-04-27
PCT/JP1999/002237 WO1999055332A1 (fr) 1998-04-27 1999-04-26 Compositions medicinales

Publications (2)

Publication Number Publication Date
DE69936195D1 true DE69936195D1 (de) 2007-07-12
DE69936195T2 DE69936195T2 (de) 2007-09-13

Family

ID=14707636

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69936195T Expired - Lifetime DE69936195T2 (de) 1998-04-27 1999-04-26 Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus)

Country Status (24)

Country Link
US (2) US6673808B1 (de)
EP (1) EP1074255B1 (de)
JP (1) JP3732525B2 (de)
KR (1) KR100406823B1 (de)
CN (1) CN1161117C (de)
AR (1) AR018330A1 (de)
AT (1) ATE363275T1 (de)
AU (1) AU749475B2 (de)
BR (1) BR9910336A (de)
CA (1) CA2326222C (de)
DE (1) DE69936195T2 (de)
ES (1) ES2284248T3 (de)
HK (1) HK1038884B (de)
HU (1) HUP0104452A3 (de)
ID (1) ID29262A (de)
IL (1) IL139210A (de)
NO (1) NO20005399L (de)
NZ (1) NZ507345A (de)
PL (1) PL343627A1 (de)
RU (1) RU2203058C2 (de)
TR (1) TR200003108T2 (de)
TW (1) TW565461B (de)
WO (1) WO1999055332A1 (de)
ZA (1) ZA200005378B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
EP1173177B2 (de) * 1999-04-30 2014-03-05 Sucampo AG Verwendung von makroliden zur behandlung von trockenen augen
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
PT2269603E (pt) * 2001-02-19 2015-09-09 Novartis Ag Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
AR038628A1 (es) * 2002-03-04 2005-01-19 Novartis Ag Composicion oftalmica
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
KR101284710B1 (ko) 2004-03-03 2013-07-23 레반스 테라퓨틱스, 아이엔씨. 국소 진단제 및 치료제의 수송을 위한 조성물 및 방법
JP4579920B2 (ja) * 2004-06-24 2010-11-10 興和株式会社 アトルバスタチン外用剤組成物
BRPI0608249A2 (pt) 2005-03-03 2009-12-08 Revance Therapeutics Inc formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
PL1904056T3 (pl) 2005-07-18 2009-09-30 Minu Llc Zastosowanie makrolidu do przywracania czucia rogówkowego
FR2900052B1 (fr) * 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
CN101288643B (zh) * 2008-06-17 2012-11-14 杨喜鸿 含有他克莫司的凝胶剂组合物及其制备方法和药物应用
US8575189B2 (en) * 2008-10-08 2013-11-05 Takata Seiyaku Co., Ltd. Tacrolimus preparation for external applications
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
JP2011102260A (ja) * 2009-11-11 2011-05-26 Takada Seiyaku Kk タクロリムス外用剤
JP5674786B2 (ja) * 2010-07-23 2015-02-25 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
WO2012011192A1 (ja) * 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
WO2012105521A1 (ja) * 2011-01-31 2012-08-09 国立大学法人大阪大学 皮膚疾患を処置するための外用薬およびその製造方法
AU2021211317A1 (en) * 2020-01-24 2022-09-01 Nobelpharma Co., Ltd. External preparation containing rapamycin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454113A (en) * 1982-09-21 1984-06-12 Scm Corporation Stabilization of oil and water emulsions using polyglycerol esters of fatty acids
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
ES2099112T3 (es) * 1990-09-04 1997-05-16 Fujisawa Pharmaceutical Co Pomadas que contienen un compuesto triciclico.
TW213418B (de) * 1991-05-02 1993-09-21 Kuko Seiyaku Kk
JPH06128148A (ja) * 1992-04-30 1994-05-10 Dotsuto:Kk 皮膚外用剤
JP2523428B2 (ja) * 1992-12-04 1996-08-07 エスエス製薬株式会社 消炎鎮痛ゲル製剤
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
DK1147766T3 (da) * 1994-10-26 2005-08-29 Novartis Ag Farmaceutiske sammensætninger
HU224814B1 (en) 1995-12-28 2006-02-28 Mitsubishi Pharma Corp Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases
CZ283516B6 (cs) * 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
TW450810B (en) * 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
EP0978288A4 (de) * 1997-04-11 2006-07-12 Astellas Pharma Inc Medizinische zusammensetzung

Also Published As

Publication number Publication date
IL139210A (en) 2005-11-20
EP1074255A1 (de) 2001-02-07
BR9910336A (pt) 2001-09-25
CA2326222A1 (en) 1999-11-04
WO1999055332A8 (fr) 2000-02-17
US6586444B2 (en) 2003-07-01
RU2203058C2 (ru) 2003-04-27
KR20010042589A (ko) 2001-05-25
AU3537299A (en) 1999-11-16
ATE363275T1 (de) 2007-06-15
DE69936195T2 (de) 2007-09-13
ZA200005378B (en) 2002-08-23
HK1038884A1 (en) 2002-04-04
CN1161117C (zh) 2004-08-11
WO1999055332A1 (fr) 1999-11-04
CN1307475A (zh) 2001-08-08
AR018330A1 (es) 2001-11-14
HUP0104452A2 (hu) 2002-03-28
TW565461B (en) 2003-12-11
AU749475B2 (en) 2002-06-27
HUP0104452A3 (en) 2004-05-28
NZ507345A (en) 2002-12-20
TR200003108T2 (tr) 2001-02-21
KR100406823B1 (ko) 2003-11-21
EP1074255A4 (de) 2002-02-13
IL139210A0 (en) 2001-11-25
HK1038884B (zh) 2005-05-06
PL343627A1 (en) 2001-08-27
US6673808B1 (en) 2004-01-06
EP1074255B1 (de) 2007-05-30
ID29262A (id) 2001-08-16
CA2326222C (en) 2008-09-23
NO20005399D0 (no) 2000-10-26
US20020061907A1 (en) 2002-05-23
NO20005399L (no) 2000-10-26
JP3732525B2 (ja) 2006-01-05
ES2284248T3 (es) 2007-11-01

Similar Documents

Publication Publication Date Title
DE69936195D1 (de) Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus)
DE69726015D1 (de) Pharmazeutische zusammensetzung enthaltend koenzym q-10
ATE234078T1 (de) Pharmazeutische omeprazol-formulierung
DE69525148D1 (de) Pharmazeutische formulierung
DE69814091D1 (de) Voriconazol-enthaltende pharmazeutische zubereitungen
ATE228823T1 (de) Pharmazeutische aerosolformulierung
DE69940904D1 (de) Pharmazeutische zusammensetzung enthaltend epothilone
ATE331529T1 (de) Antigen enthaltende pharmazeutische zusammensetzung
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
NO953874D0 (no) Farmasöytisk preparat inneholdende lipofile legemidler
HUP0004534A3 (en) Pharmaceutical formulation containing olanzapine
DE69831620D1 (de) Arzneizubereitungen enthaltend Kannabinoide
DE69807420D1 (de) Pharmazeutische aerosolzusammensetzung
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
ATE432707T1 (de) Pharmazeutische zubereitung
ATE383868T1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
DE10084344T1 (de) Cyclosporin enthaltende pharmazeutische Zusammensetzung
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
DE69708130T2 (de) A-oxo-butansäuren enthaltende pharmazeutische zusammensetzung
ATE260094T1 (de) Mikronisierte bicyclische arzneistoffe enthaltende pharmazeutische zusammensetzungen
ID30032A (id) Formulasi farmasi
DE69907735D1 (de) Melatoninderivate und diese enthaltende pharmazeutische zubereitung
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20004816D0 (no) Ny farmasøytisk formulering

Legal Events

Date Code Title Description
8364 No opposition during term of opposition